Drug delivery specialist OctoPlus NV the drug delivery and development company, is to raise Euro 25 million in a funding round.
The company, which is listed on Euronext in Amsterdam, intends to use the proceeds for the further development of the lead product is Locteron, a controlled-release formulation of interferon alfa for the treatment of chronic hepatitis C, which is currently in Phase IIa clinical study with Locteron.
Further back in the pipeline is a treatment for chronic middle ear infection, which is in Phase II clinical development, a pre-clinical GLP-1 analogue product candidate for the treatment of diabetes and two pre-clinical-stage single-shot vaccines.
In addition to its in house portfolio, OctoPlus provides drug formulation and clinical scale manufacturing services.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
